DUSP9 and prostate cancer: Ten of the 17 were downregulated by deslanoside and had an inverse correlation with RFS in patients with prostate cancer, including ITGA2B, CNIH2, FBF1, PABPC1L, MMP11, DUSP9, TMEM121, SOX18, CMPK2, and MAMDC4 (Figure 5 and Figure 7).